Affective disorders and сognitive impairment in the early stages of Parkinson’s disease

Cover Page

Cite item

Full Text

Abstract

Background: Parkinson's disease (PD) is an age-related neurodegenerative disease in developed countries. The prevalence of PD ranges from 41 per 100,000 in the fourth decade of life to more than 1,900 per 100,000 in people over 80 years of age. Neurodegeneration associated with Parkinson's disease probably occurs several decades before the onset of motor symptoms. Affective and cognitive impairments are one of the most frequent non-motor manifestations of PD, which can lead to a number of adverse outcomes. Aim: to evaluate affective and cognitive impairments in patients at the early stages of PD. Methods: 61 patients with PD participated in the study. All the participants were divided into two groups depending on the presence or absence of a diagnosis of depression verified by psychiatrists: Group 1 was the main group (n=48), group 2 was the control group (n=13). The control group included patients without depression. The average age of the participants was 62.2±9.6 years. The analysis of the PD stages was carried out in both groups. In the main group, stage II PD was diagnosed in 75%, in the control group — in 31% of patients. The average duration of the disease was 2.5±1.6 years. A clinical examination was carried out using the Beck depression questionnaire, apathy scale, Spielberger anxiety questionnaire and anxiety assessment scale in PD (to assess emotional disorders), cognitive function assessment scale in PD (SHOBP-Cog, Scopa-Cog), digital symbol replacement test (symbols-numbers test), Montreal assessment Scale cognitive functions (MoCA test), a test for connecting numbers and letters, and a Stroop test (for evaluating cognitive functions). Results: It was revealed that in the early stages of PD, the prevalence of depression, clinically significant apathy, personal and reactive anxiety was high. Significantly higher rates of depression severity, depression level, apathy level and personal anxiety were noted among the patients with stage II PD compared to the patients with stage I PD. There was a marked tendency to a decrease in cognitive functions at stage I of PD, aggravated at stage II of the disease, which was confirmed by the results of the tests: a low level of cognitive functions on the Montreal scale was detected in 52%; 70% of patients, regardless of the PD stage, showed a low rate of completion of the 1st and 2nd parts of the Stroop test for their age; the results of the digital character replacement test were below normal in 75% of cases. Conclusion: The most common affective disorders in the early stages of PD are depression and anxiety. Apathy and depression have a negative impact on the cognitive functions of patients, which worsen with the progression of the disease.

About the authors

Gulnara Zh. Makhmudova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: makhmudovagzh@mail.ru

Graduate Student

Russian Federation, Moscow

Niinoya I.N. Vellovich

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: niinoja.inv@gmail.com

Graduate Student

Russian Federation, Moscow

Elena V. Shirshova

Academy of Postgraduate Education under the Federal state budgetary institution "Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency"

Author for correspondence.
Email: shirshova.ev@fnkc-fmba.ru
ORCID iD: 0000-0001-9193-0534
SPIN-code: 7491-0434

MD, PhD, Professor

Russian Federation, Moscow

References

  1. Leentjens AF, Dujardin K, Marsh L, et al. Apathy and anhedonia rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2008;23(14):2004–2014. doi: 10.1002/mds.22229
  2. Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P. Apathy in Parkinson’s disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol. 2015;14(5):518–531. doi: 10.1016/S1474-4422(15)00019-8
  3. Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3(3):243–254. doi: 10.1176/jnp.3.3.243
  4. Robert P, Onyike CU, Leentjens AF, et al. Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. Eur Psychiatry. 2009;24(2):98–104. doi: 10.1016/j.eurpsy.2008.09.001
  5. Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex. 2006; 16(7):916–928. doi: 10.1093/cercor/bhj043
  6. Marin RS, Firinciogullari S, Biedrzycki RC. Group differences in the relationship between apathy and depression. J Nerv Ment Dis. 1994;182(4):235–239. doi: 10.1097/00005053-199404000-00008
  7. Andersson S, Krogstad JM, Finset A. Apathy and depressed mood in acquired brain damage: relationship to lesion localization and psychophysiological reactivity. Psychol Med. 1999;29(2): 447–456. doi: 10.1017/s0033291798008046
  8. Kuzis G, Sabe L, Tiberti C, et al. Explicit and implicit learning in patients with Alzheimer disease and Parkinson disease with dementia. Neuropsychiatry Neuropsychol Behav Neurol. 1999; 12(4):265–269.
  9. Kirsch-Darrow L, Fernandez HH, Marsiske M, et al. Dissociating apathy and depression in Parkinson disease. Neurology. 2006;67(1):33–38. doi: 10.1212/01.wnl.0000230572.07791.22
  10. Dujardin K. [Apathy a neurodegenerative disease: pathophysiology, diagnostic evaluation, and treatment (In French)]. Rev Neurol (Paris). 2007;163(5):513–521. doi: 10.1016/s0035-3787(07)90458-0
  11. Pedersen KF, Alves G, Aarsland D, Larsen JP. Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study. J Neurol Neurosurg Psychiatry. 2009;80(11): 1279–1282. doi: 10.1136/jnnp.2008.170043
  12. Oguru M, Tachibana H, Toda K, et al. Apathy and depression in Parkinson disease. J Geriatr Psychiatry Neurol. 2010;23(1): 35–41. doi: 10.1177/0891988709351834
  13. Ziropadja LJ, Stefanova E, Petrovic M, et al. Apathy and depression in Parkinson’s disease: the Belgrade PD study report. Parkinsonism Relat Disord. 2012;18(4):339–342. doi: 10.1016/j.parkreldis.2011.11.020
  14. Marin RS, Firinciogullari S, Biedrzycki RC. The sources of convergence between measures of apathy and depression. J Affect Disord. 1993;28(2):7–14. doi: 10.1016/0165-0327(93)90072-r
  15. Marin RS, Firinciogullari S, Biedrzycki RC. Group differences in the relationship between apathy and depression. J Nerv Ment Dis. 1994;182(4):235–239. doi: 10.1097/00005053-199404000-00008
  16. Landes AM, Sperry SD, Strauss ME, Geldmacher DS. Apathy in Alzheimer’s disease. J Am Geriatr Soc. 2001;49(12): 1700–1707. doi: 10.1046/j.1532-5415.2001.49282.x
  17. Boyle PA, Malloy PF. Treating apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2004;17(1-2):91–99. doi: 10.1159/000074280
  18. Ziropadja LJ, Stefanova E, Petrovic M, et al. Apathy and depression in Parkinson’s disease: the Belgrade PD study report. Parkinsonism Relat Disord. 2012;18(4):339–342. doi: 10.1016/j.parkreldis.2011.11.020
  19. Thobois S, Prange S, Sgambato-Faure V, et al. Imaging the etiology of apathy, anxiety, and depression in Parkinson’s disease: implication for treatment. Curr Neurol Neurosci Rep. 2017;17(10):76. doi: 10.1007/s11910-017-0788-0
  20. Kudlicka A, Clare L, Hindle JV. Executive functions in Parkinson’s disease: systematic review and meta-analysis. Mov Disord. 2011;26(13):2305–2315. doi: 10.1002/mds.23868
  21. Alzahrani H, Venneri A. Cognitive and neuroanatomical correlates of neuropsychiatric symptoms in Parkinson’s disease: a systematic review. J Neurol Sci. 2015;356(1-2):32–44. doi: 10.1016/j.jns.2015.06.037
  22. Mak E, Su L, Williams GB, O’Brien JT. Neuroimaging correlates of cognitive impairment and dementia in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(8):862–870. doi: 10.1016/j.parkreldis.2015.05.013
  23. Veselý B, Rektor I. The contribution of white matter lesions (WML) to Parkinson’s disease cognitive impairment symptoms: A critical review of the literature. Parkinsonism Relat Disord. 2016; 22(Suppl 1):S166–170. doi: 10.1016/j.parkreldis.2015.09.019
  24. Varanese S, Perfetti B, Ghilardi MF, Di Rocco A. Apathy, but not depression, reflects inefficient cognitive strategies in Parkinson’s disease. PLoS One. 2011;6(3):e17846. doi: 10.1371/journal.pone.0017846
  25. Robert G, Le Jeune F, Lozachmeur C, et al. Apathy in patients with Parkinson disease without dementia or depression A PET study. Neurology. 2012;79(11):1155–1160. doi: 10.1212/WNL.0b013e3182698c75
  26. Bogdanova Y, Cronin-Golomb A. Alexithymia and apathy in Parkinson’s disease: neurocognitive correlates. Behav Neurol. 2013;27(4):535–545. doi: 10.1155/2013/682393
  27. Collette F, Hogge M, Salmon E, van der Linden M. Exploration of the neural substrates of executive functioning by functional neuroimaging. Neuroscience. 2006;139(1):209–221. doi: 10.1016/j.neuroscience.2005.05.035
  28. Reijnders JS, Scholtissen B, Weber WE, et al. Neuroanatomical correlates of apathy in Parkinson’s disease: a magnetic resonance imaging study using voxel-based morphometry. Mov Disord. 2010;25(14):2318–2325. doi: 10.1002/mds.23268
  29. Isella V, Melzi P, Grimaldi M, et al. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson’s disease. Mov Disord. 2002;17(2):366–371. doi: 10.1002/mds.10041.
  30. Robert G, Le Jeune F, Lozachmeur C, et al. Apathy in patients with Parkinson disease without dementia or depression a PET study. Neurology. 2012;79(11):1155–1160. doi: 10.1212/WNL.0b013e3182698c75
  31. Sawamoto N, Piccini P, Hotton G, et al. Cognitive deficits and striato-frontal dopamine release in Parkinson’s disease. Brain. 2008;131(Pt 5):1294–1302. doi: 10.1093/brain/awn054
  32. Jokinen P, Brück A, Aalto S, et al. Impaired cognitive performance in Parkinson’s disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord. 2009;15(2):88–93. doi: 10.1016/j.parkreldis.2008.03.005
  33. Impaired cognitive performance in Parkinson’s disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord. 2009;15(2):88–93. doi: 10.1016/j.parkreldis.2008.03.005
  34. Ekman U, Eriksson J, Forsgren L, et al. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson’s disease and mild cognitive impairment: a cross-sectional study. Lancet Neurol. 2012;11(8):679–687. doi: 10.1016/S1474-4422(12)70138-2
  35. Polito C, Berti V, Ramat S, et al. Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson’s disease. Neurobiol Aging. 2012; 33(1):206.e29–39. doi: 10.1016/j.neurobiolaging.2010.09.004
  36. Dubois B, Pillon B. Do cognitive changes of Parkinson’s disease result from dopamine depletion? J Neural Transm. 1995; 45(Suppl):27–34.
  37. Aalto S, Brück A, Laine M, et al. Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C] FLB 457. J Neurosci. 2005;25(10):2471–2477. doi: 10.1523/JNEUROSCI.2097-04.2005
  38. Ekman U, Eriksson J, Forsgren L, et al. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson’s disease and mild cognitive impairment: a cross-sectional study. Lancet Neurol. 2012;11(8):679–687. doi: 10.1016/S1474-4422(12)70138-2
  39. Narayanan NS, Rodnitzky RL, Uc EY. Prefrontal dopamine signaling and cognitive symptoms of Parkinson’s disease. Rev Neurosci. 2013;24(3):267–278. doi: 10.1515/revneuro-2013-0004
  40. Matsumoto M Dopamine signals and physiological origin of cognitive dysfunction in Parkinson’s disease. Mov Disord. 2015; 30(4):472–483. doi: 10.1002/mds.26177
  41. Sawaguchi T, Goldman-Rakic PS. The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J Neurophysiol. 1994; 71(2):515–528. doi: 10.1152/jn.1994.71.2.515
  42. Landau SM, Lal R, O’Neil JP, et al. Striatal dopamine and working memory. Cereb Cortex. 2009;19(2):445–454. doi: 10.1093/cercor/bhn095
  43. Cools R. Dopaminergic control of the striatum for high-level cognition. Curr Opin Neurobiol. 2011;21(3):402–407. doi: 10.1016/j.conb.2011.04.002
  44. Schrag A, Siddiqui UF, Anastasiou Z, et al. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson’s disease: a cohort study. Lancet Neurol. 2017;16(1):66–75. doi: 10.1016/S1474-4422(16)30328-3
  45. Langston RG, Virmani T. Use of a Modified STROOP test to assess color discrimination deficit in Parkinson’s disease. Front Neurol. 2018;9:765. doi: 10.3389/fneur.2018.00765
  46. Kehagia AA, Ye R, Joyce DW, et al. Parsing the roles of the frontal lobes and basal ganglia in task control using multivoxel pattern analysis. J Cogn Neurosci. 2017;29(8):1390–1401. doi: 10.1162/jocn_a_01130
  47. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord. 2009;24(15):2175–2186. doi: 10.1002/mds.22589
  48. Khan NL, Graham E, Critchley P, et al. Parkin disease: a phenotypic study of a large case series. Brain. 2003;126(Pt 6): 1279–1292. doi: 10.1093/brain/awg142

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Makhmudova G. ., Vellovich N.I., Shirshova E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».